Tranexamic Acid in Hip Fracture Surgery

• Status: Enrolling by invitation
• Trial end date: 0000-00-00
• Target enrollment: 126
• Participant gender: Both

Summary

To determine if TXA utilization is effective at reducing transfusion rates in elderly patients undergoing surgery for treatment of a hip fractures.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Spectrum Health Hospitals
• Treatments: Tranexamic Acid
• Last Updated: 2016-09-09

Criteria

Inclusion Criteria:

• Acute, isolated, unilateral femoral neck, intertrochanteric, and per trochanteric hip fractures confirmed by anteroposterior/lateral hip radiographs, computed tomography, or magnetic resonance imaging.

• Age 65 and older

• Low energy mechanism of injury

• Hip fracture fixation performed within 48 hours

• English speaking

• Anticipated medical optimization for operative fixation

• No other major trauma

Exclusion Criteria:

• Unable to provide informed consent (dementia, limited decision making capacity)

• Admitted by medical service for significant co-morbidities

• Unable or refusal to receive blood products

• Retained hardware around the affected hip

• Infection around the affected hip

• Transfer patients with a length of stay > 24 hours at the transferring hospital

• History of deep vein thrombosis (DVT) or pulmonary embolus (PE) within the past year

• On anticoagulation treatment for DVT or PE, currently or within the past 12 months

• Diagnosis of deficient natural anticoagulation

• Known congenital thrombophilia (Deficiency of Protein C, S, Antithrombin)

• Known allergy to TXA

• History of seizure disorder

• Cardiac stent or ischemic stroke within 1 year

• Concomitant subarachnoid hemorrhage

• Active intravascular clotting

• Prisoner

• Patients undergoing percutaneous pinning of the hip fracture

• Patients with renal impairment (serum creatinine >1.5 or creatinine clearance < 50 ml/min)